newsfilter
← Latest News
Business Wire·

enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

enGene Holdings Inc. (NASDAQ:ENGN, "enGene" or the "Company")), a clinical-stage genetic medicines company whose non-viral lead investigational product detalimogene voraplasmid, (also known as detalimogene, and